阿尔尼拉姆制药公司
ALNY446.400USD
-3.180-0.71%
收盘 09/26, 16:00（美东）报价延迟15分钟
58.47B总市值
亏损市盈率 TTM
关于 阿尔尼拉姆制药公司 公司
Alnylam Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司。该公司致力于发现、开发、制造和商业化基于核糖核酸干扰 (RNAi) 的新型疗法。其上市产品包括用于治疗成人遗传性转甲状腺素介导性淀粉样变性 (hATTR) 伴多发性神经病的 AMVUTTRA (vutrisiran)；用于治疗成人 hATTR 淀粉样变性伴多发性神经病的 ONPATTRO (patisiran)；用于治疗成人急性肝卟啉症的 GIVLAARI (givosiran)；用于治疗 1 型原发性高草酸尿症的 OXLUMO (lumasiran)，以及由其合作伙伴诺华公司开发和商业化的 Leqvio (inclisiran)，用于治疗成人高胆固醇血症或混合性血脂异常。该公司的临床开发项目包括 Cemdisiran、Fitusiran、Zilebesiran、Elebsiran、Mivelsiran 和 ALN-HTT02。该公司正在开发 Cemdisiran 来治疗补体介导的疾病。
公司简介
公司代码ALNY
公司名称Alnylam Pharmaceuticals Inc
上市日期May 28, 2004
CEODr. Yvonne L. Greenstreet, M.D.
员工数量2230
证券类型Ordinary Share
年结日May 28
公司地址675 W Kendall St
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142-1168
电话16175518200
网址https://www.alnylam.com/
公司代码ALNY
上市日期May 28, 2004
CEODr. Yvonne L. Greenstreet, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.63K
+14.74%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
50.18K
+4.96%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
25.99K
-7.21%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
775.00
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.63K
+14.74%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
50.18K
+4.96%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
25.99K
-7.21%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
AMVUTTRA
309.99M
52.17%
GIVLAARI
66.97M
11.27%
Other
57.56M
9.69%
Regeneron Pharmaceuticals
51.04M
8.59%
ONPATTRO
49.49M
8.33%
其他
59.15M
9.95%
地区USD
名称
营收
占比
United States
271.44M
45.68%
Europe
146.16M
24.60%
Net revenues from collaborations
99.19M
16.69%
Rest of World
50.94M
8.57%
Royalty revenue
26.47M
4.45%
业务
地区
业务USD
名称
营收
占比
AMVUTTRA
309.99M
52.17%
GIVLAARI
66.97M
11.27%
Other
57.56M
9.69%
Regeneron Pharmaceuticals
51.04M
8.59%
ONPATTRO
49.49M
8.33%
其他
59.15M
9.95%
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Capital World Investors
12.82%
Fidelity Management & Research Company LLC
11.48%
The Vanguard Group, Inc.
10.10%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
4.98%
其他
55.13%
持股股东
持股股东
占比
Capital World Investors
12.82%
Fidelity Management & Research Company LLC
11.48%
The Vanguard Group, Inc.
10.10%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
4.98%
其他
55.13%
股东类型
持股股东
占比
Investment Advisor
67.79%
Investment Advisor/Hedge Fund
21.50%
Hedge Fund
3.75%
Corporation
3.39%
Research Firm
1.74%
Sovereign Wealth Fund
1.65%
Pension Fund
1.31%
Bank and Trust
1.08%
Individual Investor
0.40%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
1300
131.78M
100.54%
-3.28M
2025Q1
1315
132.55M
101.67%
-2.42M
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital World Investors
16.75M
12.85%
+149.10K
+0.90%
Mar 31, 2025
Fidelity Management & Research Company LLC
14.62M
11.22%
+1.68M
+13.00%
Mar 31, 2025
The Vanguard Group, Inc.
13.00M
9.97%
+322.72K
+2.55%
Mar 31, 2025
Capital Research Global Investors
7.15M
5.49%
+186.22K
+2.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.73M
5.16%
-22.21K
-0.33%
Mar 31, 2025
Regeneron Pharmaceuticals Inc
4.44M
3.41%
--
--
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
4.42M
3.39%
+33.70K
+0.77%
Mar 31, 2025
Dodge & Cox
3.35M
2.57%
-188.50K
-5.32%
Mar 31, 2025
State Street Global Advisors (US)
3.37M
2.58%
-56.29K
-1.64%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.41M
2.61%
+178.26K
+5.52%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
Invesco Biotechnology & Genome ETF
7.04%
VanEck Biotech ETF
6.46%
Global X Genomics & Biotechnology ETF
6.23%
Invesco Nasdaq Biotechnology ETF
5.46%
iShares Biotechnology ETF
5.37%
ProShares Ultra Nasdaq Biotechnology
4.76%
First Trust NYSE Arca Biotechnology Index Fund
4.75%
Franklin Genomic Advancements ETF
4.69%
SPDR S&P Biotech ETF
3.66%
Simplify Next Intangible Core Index ETF
3.6%
查看更多
Invesco Biotechnology & Genome ETF
占比7.04%
VanEck Biotech ETF
占比6.46%
Global X Genomics & Biotechnology ETF
占比6.23%
Invesco Nasdaq Biotechnology ETF
占比5.46%
iShares Biotechnology ETF
占比5.37%
ProShares Ultra Nasdaq Biotechnology
占比4.76%
First Trust NYSE Arca Biotechnology Index Fund
占比4.75%
Franklin Genomic Advancements ETF
占比4.69%
SPDR S&P Biotech ETF
占比3.66%
Simplify Next Intangible Core Index ETF
占比3.6%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
